Timing of DWI-MRI predicts breast cancer response
Diffusion-weighted MR images acquired 12 weeks after the start of neoadjuvant...Read more on AuntMinnie.comRelated Reading: Breast cancer follow-up imaging varies widely Breast MRI underutilized in high-risk women Multiparametric MRI shines for suspected breast cancer Is screening breast MRI being used in the wrong women? Breast MRI technique helps cancer detection without contrast
ConclusionsAlthough non-adherence was relatively infrequent in this population-based study, its impact on the risk of recurrence and mortality was considerable. Clinicians should make efforts to ensure therapeutic adherence during clinical follow-up of women with breast cancer.
ConclusionAFT does not increase breast cancer recurrence, with the possible exception of late LRRs for Luminal A patients, but further clinical and preclinical data are required to better clarify this data. The use of AFT should not be discouraged.
Condition: Breast Cancer Stage Intervention: Drug: nab-paclitaxel Sponsor: Jilin University Not yet recruiting
ConclusionMetaBC is poorly responsive to NAC, with a pCR rate (11%), that is lower than expected in a predominantly TNBC cohort. MetaBC patients should be considered for clinical trials testing new NAC regimens and in the absence of clinical trial enrollment, MetaBC patients with resectable disease should proceed directly to definitive operative management.
ConclusionsFrom our data we conclude that post-nCT miR-18a expression in breast cancer serves as a negative prognostic marker, especially in luminal tumors. Clinical, in vitro and in silico data support the role of miR-18a in breast cancer cell proliferation and endocrine resistance and suggest its potential utility as a biomarker for additional adjuvant treatment in patients without a pathologic complete response to neoadjuvant therapy.
ConclusionSNB application after PST for breast cancer in node positive patients at presentation is increasing. Pre-operative axillary imaging and tumour biology help identify patients who might be candidates for SNB as a single staging procedure.
Opinion statementOral inhibitors of CDK4/6 have been shown to increase response rates and prolong disease control when combined with endocrine therapy in hormone-responsive (HR+) HER2-negative advanced breast cancer. Palbociclib, ribociclib and abemaciclib are all approved in combination with non-steroidal aromatase inhibitors in first-line therapy for post-menopausal women, with a 40 –45% improvement in progression-free survival seen with the addition of any of these CDK4/6 inhibitors. Additional approved indications, including first- and second-line combination therapy for pre-menopausal women, combination with ful...
Objectives: To investigate the relationship between the expression of ER, PR, HER-2 and Ki-67 and the effective rates of neoadjuvant chemotherapy (NAC), and to study the influence of NAC on the expression of ER, PR, HER-2 and Ki-67 in breast cancer patients.
Conclusion.Neoadjuvant therapy has clinical benefits in early breast cancer and provides in vivo information of individual breast cancer biology while allowing the investigation of new treatment approaches. Access to neoadjuvant therapy should be an option available to all patients with breast cancer through multidisciplinary tumor management.Implications for Practice.Neoadjuvant treatment should be strongly considered as a therapeutic option for localized breast cancer and is a powerful tool for understanding breast cancer biology and investigating new treatment approaches.
Condition: HER2 Positive Breast Cancer Intervention: Drug: Pyrotinib and Trastuzumab plus Vinorelbine Sponsor: Henan Cancer Hospital Not yet recruiting